An early-stage biotech company faced challenges in developing a small molecule protein-protein interaction inhibitor through a biochemical screen. Their project was stalled with their current CRO, who failed to deliver a suitable protein. Learn how Tango Biosciences screened multiple peptide libraries in parallel to identify a peptide binder in lieu of the protein for use in biochemical assays for small molecule screening, and also opened avenues for the company to pursue peptide therapeutics.
Subscribe to our email newsletter to access this Case Study
We promise not to spam you, only share relevant updates about Tango Biosciences.
"*" indicates required fields
